Revium Recovery 

$1.4300
1
+$0.00+0%Wednesday 20:00

Statistics

Day High
1.43
Day Low
1.43
52W High
1.67
52W Low
0.52
Volume
248
Avg. Volume
3
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie manufactures and markets Humira, which is used in the treatment of autoimmune diseases, competing with Revium's therapies.
AMGEN
AMGN
Mkt Cap251.94B
Amgen produces Enbrel, a direct competitor to some of Revium Recovery's autoimmune treatment options.
Pfizer
PFE
Mkt Cap173.95B
Pfizer offers various drugs that compete in the autoimmune and inflammation markets, overlapping with Revium Recovery's product lines.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, provides several drugs that compete in the same therapeutic areas as Revium Recovery.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on innovative therapies for neurological and neurodegenerative diseases, competing with Revium's neurological disorder treatments.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences offers treatments for HIV/AIDS, liver diseases, and other conditions, competing with Revium Recovery in the specialty treatment market.
Novartis
NVS
Mkt Cap303.67B
Novartis provides a wide range of healthcare solutions, including treatments for autoimmune diseases, directly competing with Revium Recovery.
Merck
MRK
Mkt Cap368.89B
Merck produces drugs that target various diseases, including those in Revium Recovery's therapeutic areas, making them a competitor.
Roche
RHHBY
Mkt Cap334.28B
Roche, with its diverse portfolio, including treatments for cancer and autoimmune diseases, competes with Revium Recovery's offerings.
Sanofi
SNY
Mkt Cap106.24B
Sanofi focuses on areas such as immunology and inflammation, directly competing with Revium Recovery in the development of treatments for similar conditions.

About

Operating from its Irvine, California headquarters, Revium Recovery Inc. is a United States-based entity engaged in the production and commercialization of an extensive portfolio of both alcoholic and non-alcoholic drinks. Its product catalog features a variety of specialized waters (structured and flavored), a selection of sports and energy beverages, green tea, and a range of spirits. The company also holds a significant strategic collaboration with Quantum TecH20. This enterprise, initially named OC Beverages, Inc., rebranded to Revium Recovery Inc. in December of 2020.
Show More
CEO
Amir Avraham
Employees
1
Country
Israel
ISIN
US76151C1009

Listings

0 Comments

Share your thoughts

FAQs

What is Revium Recovery stock price today?▼
The current price of RVRC is $1.43 USD — it has increased by +0% in the past 24 hours. Watch Revium Recovery stock price performance more closely on the chart.
What is Revium Recovery stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Revium Recovery stocks are traded under the ticker RVRC.
Is Revium Recovery stock price growing?▼
RVRC stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Revium Recovery has showed a +175% increase.
How many employees does Revium Recovery have?▼
As of November 2, 2026, the company has 1 employees.
In which sector is Revium Recovery located?▼
Revium Recovery operates in the Health & Wellness sector.
When did Revium Recovery complete a stock split?▼
The last stock split for Revium Recovery was on December 9, 2020 with a ratio of 1:500.
Where is Revium Recovery headquartered?▼
Revium Recovery is headquartered in Herzliya, Israel.